HIV/HBV coinfection in children and antiviral therapy.
HIV/HBV coinfection in children and antiviral therapy.
复制标题
DOI：
10.1586/eri.13.2
复制
发表时间：
2013-03
影响因子：
5.7
通讯作者：
Melvin AJ
中科院分区：
文献类型：
--
作者：
Healy SA;Gupta S;Melvin AJ
来自 HIV 和 HBV 流行国家的小规模队列研究表明，HIV 感染儿童的慢性乙型肝炎患病率在 1% 至 49% 之间。虽然关于双重感染儿童的数据有限，但对 HIV/HBV 双重感染成人的研究结果引起了人们的关注，即双重感染儿童可能面临更高的肝病、肝纤维化和肝硬化风险。随着世界范围内联合抗逆转录病毒治疗的扩大，其中拉米夫定被纳入大多数一线治疗方案中，接受拉米夫定治疗的合并感染儿童存在发生乙型肝炎病毒耐药突变的风险。本文总结了与儿童 HIV/HBV 合并感染相关的现有文献、治疗选择，并强调了未来研究的重点。
Small cohort studies from countries where both HIV and HBV are endemic demonstrate prevalence rates of chronic hepatitis B in HIV-infected children of between 1 and 49%. While data on coinfected children are limited, results from studies in adults with HIV/HBV coinfection raise the concern that coinfected children may be at a higher risk of liver disease, hepatic fibrosis and cirrhosis. With the scale-up of combination antiretroviral therapy worldwide, of which lamivudine is included in most first-line regimens, coinfected children treated with lamivudine risk development of HBV resistance mutations. This article summarizes the current literature relevant to HIV/HBV coinfection in children, the options for treatment and highlights priorities for future research.